Denosumab inhibits osteoclast activation and promotes bone deposition, and its specificity and affinity for RANKL is higher than that of RANK, blocking the RANK/RANKL signaling pathway by binding to RANKL and thus inhibiting the interaction between neoplastic stromal cells and multinucleated giant cells, which is closely associated with tumor recurrence (10). The gene discussed is TNFSF11; the disease is neoplasm.